The progression of cardiometabolic disease: Validation of a new cardiometabolic disease staging system applicable to obesity. (5th September 2013)

• Record Type: Journal Article
• Authors: Guo, Fangjian; Moellering, Douglas R.; Garvey, W. Timothy
• Is Part Of: Obesity. Volume 22(2014:Feb.)Supplement 1
• Page Start: 110
• Page End: 118
• Publication Date: 2013-09-05
• Subjects: Obesity -- Periodicals; 616.398005
• DOI: 10.1002/oby.20585
• Languages: English
• ISSNs: 1930-7381

Abstract

Abstract : Objective: To validate a Cardiometabolic Disease Staging (CMDS) system for assigning risk level for diabetes, and all‐cause and cardiovascular disease (CVD) mortality. Design and Methods: Two large national cohorts, CARDIA and NHANES III, were used to validate CMDS. CMDS: Stage 0: metabolically healthy; Stage 1: one or two metabolic syndrome risk factors [other than impaired fasting glucose (IFG)]; Stage 2: IFG or impaired glucose tolerance (IGT) or metabolic syndrome (without IFG); Stage 3: two of three (IFG, IGT, and/or metabolic syndrome); and Stage 4: type 2 diabetes mellitus/CVD. Results: In the CARDIA study, compared with Stage 0 metabolically healthy subjects, adjusted risk for diabetes exponentially increased from Stage 1 [hazard ratio (HR) 2.83, 95% confidence interval (CI): 1.76‐4.55], to Stage 2 (HR 8.06, 95% CI 4.91‐13.2), to Stage 3 (HR 23.5, 95% CI 13.7‐40.1) ( P for trend <0.001). In NHANES III, both cumulative incidence and multivariable adjusted HRs markedly increased for both all‐cause and CVD mortality with advancement of the risk stage from Stages 0 to 4. Adjustment for body mass index (BMI) minimally affected the risks for diabetes and all‐cause/CVD mortality using CMDS. Conclusion: CMDS can discriminate a wide range of risk for diabetes, CVD mortality, and all‐cause mortality independent of BMI, and should be studied as a risk assessment tool to guide interventions that prevent and treat cardiometabolic disease.